A study found that covid-19 vaccines appeared to awaken the immune system in lung and skin cancer patients, helping them live ...

Monday that a global tier-one pharmaceutical partner had started dosing patients in a phase one and two US clinical trial ...

Scientists in NSW have developed a potential world-first mRNA vaccine to protect cattle from foot and mouth disease. The ...

Investing.com -- 4basebio PLC (AIM:4BB) stock surged 6.9% on Monday after announcing that a global Tier 1 pharmaceutical partner has begun dosing patients in Phase I/II clinical trials using the ...

Cambridge, UK, 27 October 2025 - 4basebio PLC (AIM: 4BB), an innovation-led provider of novel synthetic DNA products announces that, following Investigational New Drug (IND) approval from the FDA, a ...

Therapeutics and Global Markets" report has been added to ResearchAndMarkets.com's offering.The global market for mRNA therapeutics was valued at $7.71 billion in 2025 and is forecast to remain stable ...

The partner firm has used 4basebio's template to develop an mRNA product which has been tested on patients in phase-one and two clinical trials, following investigational new drug approval from the US ...

Genenta & Anemocyte ink partnership to advance off-the-shelf LVV Plasmid DNA production: Milan Monday, October 27, 2025, 14:00 Hrs [IST] Genenta Science, a pioneer company in immu ...

Fourth-year biomedical engineering candidate Yining Zhu has been named a 2026 Siebel Scholar, an honor that recognizes students in bioengineering fields for exemplary achievement in academia, research ...

A research team has discovered a previously overlooked subtype of brain tumor termed IME IDH-mutant astrocytoma. Contrary to ...

The partnership leverages Genenta's robust and well-tested LVV Plasmid DNA technology, a platform developed from the foundational research of Professor Luigi Naldini, co-founder of Genenta. This ...

UNLV scientists successfully introduced nanoparticles with messenger RNA into the pancreas for the first time with 99% accuracy.